2016
DOI: 10.1164/rccm.201508-1647oc
|View full text |Cite
|
Sign up to set email alerts
|

Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial

Abstract: Pharmacologic treatment of chronic obstructive pulmonary disease has consistent beneficial and plausible effects on cardiac function and pulmonary vasculature that may contribute to favorable effects of inhaled therapies. Future studies should investigate the effect of prolonged lung deflation on intrinsic myocardial function. Clinical trial registered with www.clinicaltrials.gov (NCT 01691885).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
81
1
8

Year Published

2016
2016
2021
2021

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 114 publications
(94 citation statements)
references
References 34 publications
4
81
1
8
Order By: Relevance
“…In addition, emphysema and airflow obstruction have been shown to influence cardiac function [21,31]. However, though a reduction in pulmonary hyperinflation induced by bronchodilator therapy has been shown to lead to a significant improvement in cardiac function [32], a large randomized controlled trial failed to show an influence of inhaled treatment with a corticosteroid and/or a longacting beta agonist on the occurrence of cardiovascular events [33]. Nevertheless, given that COPD treatment improves both pulmonary and cardiac function, patients with ACS should be thoroughly assessed for the presence of COPD and impaired pulmonary function.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, emphysema and airflow obstruction have been shown to influence cardiac function [21,31]. However, though a reduction in pulmonary hyperinflation induced by bronchodilator therapy has been shown to lead to a significant improvement in cardiac function [32], a large randomized controlled trial failed to show an influence of inhaled treatment with a corticosteroid and/or a longacting beta agonist on the occurrence of cardiovascular events [33]. Nevertheless, given that COPD treatment improves both pulmonary and cardiac function, patients with ACS should be thoroughly assessed for the presence of COPD and impaired pulmonary function.…”
Section: Discussionmentioning
confidence: 99%
“…Using magnetic resonance imaging this double-blinded placebo controlled crossover study showed that decreases in residual volume following short term treatment with combination fluticasone furoate/vilaterol combination was accompanied by improved cardiac function and increased artery pulsatilty (39). Although small, this is the first well-designed study providing evidence that pharmacologically treating hyperinflation can improve cardiac function, presumably by targeting cardiac underfilling (40).…”
Section: Cardiovascular/multimorbidity Vascular Diseases and Copdmentioning
confidence: 91%
“…Although no improvement in cardiovascular mortality or events was found by SUMMIT, Stone et al reported the use of combination fluticasone furoate/vilaterol may favourably alter cardiac function (39). Using magnetic resonance imaging this double-blinded placebo controlled crossover study showed that decreases in residual volume following short term treatment with combination fluticasone furoate/vilaterol combination was accompanied by improved cardiac function and increased artery pulsatilty (39).…”
Section: Cardiovascular/multimorbidity Vascular Diseases and Copdmentioning
confidence: 99%
“…В двойном слепом плацебо-контролируемом пере-крестном рандомизированном исследовании с уча-стием 90 больных ХОБЛ, проведенном Stone I.S. и соавт., у 45 пациентов оценено влияние легочной де-фляции на структурно-функциональные параметры сердца на фоне 7/14-дневной терапии комбинацией флютиказонафуроата/вилантерола (100/25 мкг) [36]. К участию в исследовании допускались больные ХОБЛ с увеличением остаточного объема легких (>120% от должных величин), подтверждающего на-личие легочной гиперинфляции.…”
Section: Heart Remodelling In Patients With Copdunclassified